Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5394872 | PMC |
| http://dx.doi.org/10.3324/haematol.2016.146894 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Potential Drug Synergy Through the ERBB2 Pathway in HER2+ Breast Tumors.
Int J Mol Sci
November 2024
Computational Genomics Division, National Institute of Genomic Medicine, Mexico City 14610, Mexico.
HER2-positive (HER2+) breast cancer is characterized by the overexpression of the ERBB2 (HER2) gene, which promotes aggressive tumor growth and poor prognosis. Targeting the ERBB2 pathway with single-agent therapies has shown limited efficacy due to resistance mechanisms and the complexity of gene interactions within the tumor microenvironment. This study aims to explore potential drug synergies by analyzing gene-drug interactions and combination therapies that target the ERBB2 pathway in HER2+ breast tumors.
View Article and Find Full Text PDFPiperlongumine in combination with EGFR tyrosine kinase inhibitors for the treatment of lung cancer cells.
Oncol Res
October 2024
Department of Pharmaceutical Sciences, Massachusetts College of Pharmacy and Health Sciences, Worcester, MA 01608, USA.
Objectives: EGFR tyrosine kinase inhibitor (EGFR-TKI) therapies such as erlotinib and gefitinib are approved for the treatment of non-small cell lung cancer (NSCLC). However, the high incidence of acquired resistance to these EGFR-TKIs may preclude their effectiveness. Piperlongumine (PPL), an extract from the long pepper fruit (), has been shown to possess anticancer properties.
View Article and Find Full Text PDFIntegrated microbiome and metabolome analysis reveals synergistic efficacy of basil polysaccharide and gefitinib in lung cancer through modulation of gut microbiota and fecal metabolites.
Int J Biol Macromol
November 2024
State Key Laboratory of Dampness Syndrome of Chinese Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou 510120, China; Department of Pharmacology of Traditional Chinese Medicine, The Second Clinical College of Guangzhou University of Chinese Medicine, Guangzhou 510120, China; Guangdong-Hong Kong-Macau Joint Lab on Chinese Medicine and Immune Disease Research, The Second Clinical College of Guangzhou University of Chinese Medicine, Guangzhou 510120, China; Department of Pathology, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou 510120, China. Electronic address:
Article Synopsis
- Emerging evidence highlights the interplay between gut microbiota and the effectiveness of EGFR-TKIs like gefitinib and erlotinib in lung cancer therapy.
- Plant polysaccharides, particularly basil polysaccharide (BPS), may alter gut microbiota, impacting drug metabolism and overall treatment outcomes.
- This study utilized a gefitinib-resistant mouse model and a multi-omics approach to show that BPS can enhance the anti-tumor effects of gefitinib by modifying the gut microbiota and its metabolites, potentially improving cancer signaling pathways and treatment efficacy.
Combinatorial Delivery of Docetaxel- and Erlotinib-Loaded Functionalized Nanostructured Lipid Carriers for the Treatment of Triple-Negative Breast Cancer Using Quality-by-Design Approach.
Pharmaceutics
July 2024
Department of Pharmaceutical Engineering and Technology, IIT (BHU), Varanasi 221005, India.
This study explored the combined administration of docetaxel (DOC) and erlotinib (ERL) using nanostructured lipid carriers (NLCs), with folic acid (FA) conjugation to enhance their synergistic anticancer efficacy against triple-negative breast cancer. NLCs were developed through hot melt homogenization-ultrasound dispersion, and optimized by a quality-by-design (QbD) approach using Plackett-Burman design and Box-Behnken design. Plots were generated based on maximum desirability.
View Article and Find Full Text PDFFunctional genomics reveals an off-target dependency of drug synergy in gastric cancer therapy.
Gastric Cancer
November 2024
Koç University Research Center for Translational Medicine, 34450, Istanbul, Turkey.
Background: Integrating molecular-targeted agents into combination chemotherapy is transformative for enhancing treatment outcomes in cancer. However, realizing the full potential of this approach requires a clear comprehension of the genetic dependencies underlying drug synergy. While the interactions between conventional chemotherapeutics are well-explored, the interplay of molecular-targeted agents with conventional chemotherapeutics remains a frontier in cancer treatment.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!